Global Vacuum-assisted Biopsy Devices Market Size By Type (9-12G, <9G), By Application (Hospitals, Academic and Research Institutes), By Region, And Segment Forecasts, 2023 to 2032

The Global Vacuum-assisted Biopsy Devices Market was valued at USD 915 million in 2023 and is projected to surpass USD 1.72 billion by 2031, growing at a CAGR of 8.3% during the forecast period from 2023 to 2031. The market growth is driven by the increasing prevalence of breast cancer and other soft tissue malignancies, rising awareness of minimally invasive diagnostic techniques, and continuous technological advancements in biopsy systems. Vacuum-assisted biopsy (VAB) devices are becoming a preferred choice over traditional biopsy techniques due to their precision, reduced invasiveness, and enhanced sample quality.

Drivers:

1. Rising Incidence of Cancer:

Globally, the increasing number of cancer diagnoses, particularly breast cancer, is contributing to higher demand for accurate and minimally invasive diagnostic methods such as vacuum-assisted biopsy.

2. Technological Advancements in Biopsy Devices:

Modern VAB devices offer real-time imaging integration, ergonomic design, and enhanced tissue acquisition, leading to more effective and faster diagnoses, which boosts their adoption in hospitals and diagnostic centers.

3. Preference for Minimally Invasive Procedures:

The shift towards outpatient and image-guided diagnostic procedures due to their safety, faster recovery, and cost-effectiveness supports market growth for vacuum-assisted biopsy systems.

Restraints:

1. High Equipment Costs:

Despite long-term cost benefits, the high initial investment and maintenance costs of vacuum-assisted biopsy systems may hinder adoption, especially in low- and middle-income countries.

2. Limited Availability in Rural Areas:

Access to advanced diagnostic tools remains limited in underdeveloped regions, constraining overall market expansion.

Opportunity:

1. Market Expansion in Emerging Economies:

Developing nations with increasing healthcare budgets and improving diagnostic infrastructure present significant opportunities for VAB device manufacturers.

2. Integration with AI and Advanced Imaging:

The integration of VAB systems with AI and 3D imaging is expected to revolutionize cancer diagnostics, opening new avenues for innovation and precision medicine.

Market by System Type Insights:

The Handheld Vacuum-assisted Biopsy Devices segment dominated the market in 2023, attributed to its portability, cost-effectiveness, and wide applicability across imaging modalities like ultrasound and mammography. Meanwhile, table-top systems are gaining traction in hospitals and specialized diagnostic clinics for high-volume sample processing and accuracy in complex cases.

Market by End-use Insights:

The Hospitals and Clinics segment held the largest share in 2023, owing to the widespread availability of imaging equipment and skilled personnel. However, the Ambulatory Surgical Centers (ASCs) segment is expected to witness the fastest growth due to the growing preference for outpatient procedures and lower treatment costs.

Market by Regional Insights:

North America accounted for the largest revenue share in 2023, driven by a high cancer incidence rate, favorable reimbursement scenarios, and technological advancements. Asia-Pacific is projected to be the fastest-growing region, supported by rapid urbanization, rising healthcare expenditure, and increasing awareness of early cancer screening programs in countries like China and India.

Competitive Scenario:

Key players in the Global Vacuum-assisted Biopsy Devices Market include Hologic, Inc., BD (Becton, Dickinson and Company), Devicor Medical Products, Inc. (a Leica Biosystems company), Argon Medical Devices, Olympus Corporation, Cardinal Health, and Cook Medical. These companies focus on product development, regulatory approvals, and strategic collaborations to strengthen their global presence.

Scope of Work – Global Vacuum-assisted Biopsy Devices Market

Report Metric Details

Market Size (2023) USD 915 million

Projected Market Size (2031) USD 1.72 billion

CAGR (2023-2031) 8.3%

Market Segments By System Type, End-use, Region

Growth Drivers Rising cancer incidence, minimally invasive trends, technological innovation

Opportunities AI integration, emerging markets, outpatient diagnostic trends

Key Market Developments:

2023: Hologic launched the Brevera® breast biopsy system with CorLumina® imaging technology, enabling real-time image verification during biopsy.

2024: BD received FDA clearance for its next-gen VAB system optimized for ultrasound-guided breast biopsies.

2025: Devicor Medical expanded its global distribution network in Asia-Pacific to meet rising regional demand for minimally invasive biopsy tools.

FAQs:

1) What is the current market size of the Global Vacuum-assisted Biopsy Devices Market?

The market was valued at USD 915 million in 2023.

2) What is the major growth driver of the Global Vacuum-assisted Biopsy Devices Market?

The rising prevalence of cancer and the preference for minimally invasive diagnostic techniques are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Vacuum-assisted Biopsy Devices Market?

North America holds the largest market share due to high adoption of advanced diagnostic technologies.

4) Which segment accounted for the largest market share in the Global Vacuum-assisted Biopsy Devices Market?

The Hospitals and Clinics segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Vacuum-assisted Biopsy Devices Market?

Key players include Hologic, BD, Devicor Medical Products, Argon Medical Devices, Olympus Corporation, and Cook Medical.

Would you like a visual chart for market segmentation or CAGR trend?